+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of sodium hypochlorite and chlorhexidine as disinfectants on post-operative pain and the success of partial caries removal in mature permanent mandibular molars with deep carious lesions and moderate pulpitis. The study aims to compare the clinical and radiographic outcomes after partial caries removal using these disinfectants versus saline. The research focuses on improving treatment results for deep dental cavities while monitoring pain reduction after the procedure. Participants will undergo partial caries removal followed by cavity disinfection with either 2% chlorhexidine, 5.25% sodium hypochlorite, or saline control group. The study includes randomized allocation into one of three groups no disinfectant, sodium hypochlorite disinfection, or chlorhexidine disinfection. Treatment success will be assessed after 12 months, while post-operative pain will be monitored daily for one week. During the study, participants will receive clinical and radiographic evaluations at 12 months to measure the success of the treatment. Pain assessments will be conducted every 24 hours for seven days following the procedure. The research team will track both clinical and radiographic success criteria and monitor pain levels to evaluate the effectiveness of the disinfectants used. The total follow-up period for the primary outcomes is 12 months.

Age: 18Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the healing outcomes and quality of life in patients with apico-marginal defects and interproximal involvement related to endodontic and periapical diseases. The study compares the combined use of PRF-Medium plug and acellular chorionic membrane ACM with conventional endodontic surgery techniques. It focuses on patients with non-vital teeth suffering from chronic suppurative apical periodontitis and persistent defects, assessing whether this new combination improves recovery and patient wellbeing. Participants will undergo endodontic micro-surgery, where one group receives surgery with the placement of PRF-Medium plug and ACM membrane, while the comparison group undergoes surgery without these materials. The study involves two groups one treated with guided tissue regeneration GTR using the ACM membrane and PRF plug, and the other with surgery alone. The interventions are randomized, and the study employs triple masking to reduce bias. Throughout the 12 months following surgery, participants will be monitored with 2D periapical radiographs and 3D cone-beam computed tomography CBCT imaging to assess periapical healing. Quality of life assessments are also conducted from baseline to 12 months to evaluate patient outcomes. The study includes regular follow-ups to measure healing progress and patient-reported wellbeing, with the total participation duration being one year.

Age: 16Years +All GendersPhase Not Applicable
1 location
G

Actively Recruiting

Researchers are evaluating the efficacy and safety of olverembatinib compared to bosutinib in patients with chronic phase chronic myeloid leukemia CML-CP. This phase 3 randomized study includes patients previously treated with at least two tyrosine kinase inhibitors TKIs and also examines olverembatinib in a single-arm group of CML-CP patients with the T315I mutation. The study addresses treatment options for patients with limited effective therapies and includes a crossover option for those meeting failure criteria while on bosutinib. Participants in Part A will be randomly assigned to receive either olverembatinib every other day or bosutinib once daily. Part B involves patients with the T315I mutation receiving olverembatinib alone. Treatment cycles are 28 days, with pharmacokinetic assessments after the first two cycles. Patients may continue treatment and be monitored for up to five years to evaluate long-term outcomes and safety. During the study, participants will undergo assessments including molecular response rates at 24 and 96 weeks, cytogenetic response evaluations at multiple intervals, and monitoring for adverse events. Researchers will also track progression-free and overall survival. Organ function and performance status will be regularly evaluated to ensure safety and treatment adherence throughout the study duration.

Age: 18Years +All GendersPhase 3
163 locations